Recombinant protein is a kind of protein which is produced according to people's will by using the technology of genetic engineering, fermentation and protein purification. Recombinant Protein Platform, which led by professor Huang, has more than 20 years experience in the field of R&D and application of recombinant protein.Professor Huang has completed the discovery of two new class I drugs and two new biological drugs, one genetically modified biological product and one national class III drug device,.And He published more than 130 scientific research papers, of which more than 80 were SCI80.More than 40 invention patents have been applied and 24 have been authorized, including 1 international patent and 14 provincial and ministerial awards. More than 10 enterprises have been successfully incubated with related new drug technology products, which including 3 listed companies.
The recombinant protein platform, with Professor Huang yadong as the chief scientist, is one of the core platforms of Tyran, and the platform is the earliest technology platform established Tyran as well .The platform is equipped with high-efficiency microbial expression, high-throughput screening and multi-level amplification test equipment, and has a group of experienced research, development and industrialization personnel, focusing on the development and application of GRAS and food-grade expression systems, with a higher starting point, committed to improving the safety and efficacy of products.At present, the platform has successfully developed Rechprotein? HUCOLL, Rechprotein?ARGILY-L, Rechprotein?AMPS, Rechprotein?FN, Rechprotein?ARGICOLL, Rechprotein?ARGILY-P and other series of products. Currently,Tyran is providing these protein to the market.